Controlled Drug Delivery: Historical perspective for the next generation

Journal of Controlled Release

Volumn 219, Issue , 2015, Pages 2-7

  Yun, Yeon Hee ^a   Lee, Byung Kook ^a   Park, Kinam ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

Biological barriers; Drug delivery; History; Physicochemical barriers

Indexed keywords

DRUG DELIVERY; HISTORY; PHYSIOLOGY;

BIOLOGICAL BARRIER; CONTROLLED DRUG DELIVERY SYSTEMS; CONTROLLED RELEASE FORMULATIONS; DRUG DELIVERY TECHNOLOGIES; DRUG RELEASE KINETICS; HISTORICAL PERSPECTIVE; PHYSICOCHEMICAL BARRIERS; PHYSICOCHEMICAL PROPERTY;

CONTROLLED DRUG DELIVERY;

CONTROLLED SUBSTANCE; NANOPARTICLE; PEPTIDE; DRUG;

ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED RELEASE FORMULATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; HUMAN; MOLECULAR WEIGHT; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; ANIMAL; HISTORY; TRENDS;

ANIMALS; DRUG DELIVERY SYSTEMS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84947239507     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.10.005     Document Type: Article

References (48)

1. N. Davar, and S. Ghosh Oral controlled release-based products for life cycle management H. Wen, K. Park, Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice 2010 John Wiley & Sons New York, NY 305 320
2. P.I. Lee, and J.-X. Li Evolution of oral controlled release dosage forms H. Wen, K. Park, Oral Controlled Release Formulation Design and Drug Delivery 2010 John Wiley & Sons, Inc. Hoboken, NJ 21 31
3. M. Ye, S.W. Kim, and K. Park Issues in long-term protein delivery using biodegradable microparticles J. Control. Release 156 2010 241 260
4. L. Heinemann The failure of Exubera: are we beating a dead horse? J. Diabetes Sci. Technol. 2 2008 518 529
5. K. Sung Wan, P. Chaul Min, M. Kimiko, L.A. Seminoff, D.L. Holmberg, J.M. Gleeson, D.E. Wilson, and E.J. Mack Self-regulated glycosylated insulin delivery J. Control. Release 11 1990 193 201
6. L.A. Klumb, and T.A. Horbett Design of insulin delivery devices based on glucose sensitive membranes J. Control. Release 18 1992 59 80
7. J.J. Kim, and K. Park Modulated insulin delivery from glucose-sensitive hydrogel dosage forms J. Control. Release 77 2001 39 47
8. R.A. Siegel Stimuli sensitive polymers and self regulated drug delivery systems: a very partial review J. Control. Release 190 2014 337 351
9. K. Park Facing the truth about nanotechnology in drug delivery ACS Nano 7 2013 7442 7447
10. B.K. Lee, Y.H. Yun, and K. Park Smart nanoparticles for drug delivery: boundaries and opportunities Chem. Eng. Sci. 125 2015 158 164
11. M.X. Guo Dissolution testing: in vitro characterization of oral controlled release dosage forms H. Wen, K. Park, Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice 2010 John Wiley & Sons New York, NY 245 256
12. Y. Lu, S.W. Kim, and K. Park In vitro-in vivo correlation: perspectives on model development Int. J. Pharm. 418 2011 142 148
13. K. Park Controlled drug delivery systems: past forward and future back J. Control. Release 190 2014 3 8
14. H. Okada Depot injectable microcapsules of leuprorelin acetate (Lupron Depot) M. Morishita, K. Park, Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development 2009 CRC Press Boca Raton, FL 370 383
15. A. Rawat, and D.J. Burgess Parenteral delivery of peptides and proteins M. Morishita, K. Park, Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development 2009 CRC Press Boca Raton, FL 50 68
16. J.-M. Cadot In vitro-in vivo correlation: application to biotech product development M. Morishita, K. Park, Biodrug Delivery Systems: Fundamentals, Applications and Clinical Development 2009 CRC Press Boca Raton, FL 341 356
17. M. Martinez, M. Rathbone, D. Burgess, and M. Huynh In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting J. Control. Release 129 2008 79 87
18. H.E. Koschwanez, and W.M. Reichert In vitro, in vivo and post explantation testing of glucose-detecting biosensors: current methods and recommendations Biomaterials 28 2007 3687 3703
19. T. Takagi, C. Ramachandran, M. Bermejo, S. Yamashita, L.X. Yu, and G.L. Amidon A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan Mol. Pharm. 3 2006 631 643
20. D. Hörter, and J.B. Dressman Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract1 Adv. Drug Deliv. Rev. 46 2001 75 87
21. C.W. Pouton Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system Eur. J. Pharm. Sci. 29 2006 278 287
22. Y. Kawabata, K. Wada, M. Nakatani, S. Yamada, and S. Onoue Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications Int. J. Pharm. 420 2011 1 10
23. Y. Lu, and K. Park Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs Int. J. Pharm. 453 2013 198 214
24. A. Paudel, Z.A. Worku, J. Meeus, S. Guns, and G. Van den Mooter Manufacturing of solid dispersions of poorly water soluble drugs by spray drying: formulation and process considerations Int. J. Pharm. 453 2013 253 284
25. S. Sotthivirat, C. McKelvey, J. Moser, B. Rege, W. Xu, and D. Zhang Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364 Int. J. Pharm. 452 2013 73 81
26. D.D. Sun, and P.I. Lee Probing the mechanisms of drug release from amorphous solid dispersions in medium-soluble and medium-insoluble carriers J. Control. Release 211 2015 85 93
27. H. Gelderblom, J. Verweij, K. Nooter, and A. Sparreboom Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation Eur. J. Cancer 37 2001 1590 1598
28. F. Kratz Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles J. Control. Release 132 2008 171 183
29. D.A. Yardley nab-Paclitaxel mechanisms of action and delivery J. Control. Release 170 2013 365 372
30. T.Y. Kim, D.W. Kim, J.Y. Chung, S.G. Shin, S.C. Kim, D.S. Heo, N.K. Kim, and Y.J. Bang Phase I and pharmacokinetic study of Genexol-PM, a Cremophor-free, polymeric micelle-formulated paclitaxel, in patients with advanced malignancies Clin. Cancer Res. 10 2004 3708 3716
31. F.K. Engels, R.A. Mathot, and J. Verweij Alternative drug formulations of docetaxel: a review Anti-Cancer Drugs 18 2007 95 103
32. L.B. Norris, Z.P. Qureshi, P.B. Bookstaver, D.W. Raisch, M. Oliver Sartor, H. Chen, F. Chen, and C.L. Bennett Polysorbate 80 hypersensitivity reactions: a renewed call to action Commun. Oncol. 7 2010 425 428
33. A.J. Vander, D. Luciano, and J. Sherman Human Physiology: The Mechanism of Body Function Eighth Edition 2001 McGraw - Hill Boston, MA (803. pp. Ch. 17)
34. W.-C. Shen Oral peptide and protein delivery: unfulfilled promises? Drug Discov. Today 8 2003 607 608
35. Y. Yun, Y.W. Cho, and K. Park Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery Adv. Drug Deliv. Rev. 65 2013 822 832
36. A.D. Rieux, V. Fievez, M. Garinot, Y.-J. Schneider, and V. Préat Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach J. Control. Release 116 2006 1 27
37. C.F.V.D. Walle Peptide and Protein Delivery 2011 Academic Press Burlington MA 360
38. K. Park Lessons learned from thermosensitive liposomes for improved chemotherapy J. Control. Release 174 2014 219
39. K. Park Translation from mouse to human: time to think in new boxes J. Control. Release 189 2014 187
40. J.W. Nichols, and Y.H. Bae EPR: Evidence and fallacy J. Control. Release 190 2014 451 464
41. C.P. Hollis, H.L. Weiss, M. Leggas, B.M. Evers, R.A. Gemeinhart, and T. Li Biodistribution and bioimaging studies of hybrid paclitaxel nanocrystals: lessons learned of the EPR effect and image-guided drug delivery J. Control. Release 172 2013 12 21
42. Y. Barenholz Doxil® - The first FDA-approved nano-drug: lessons learned J. Control. Release 160 2012 117 134
43. D.L. Stirland, J.W. Nichols, S. Miura, and Y.H. Bae Mind the gap: a survey of how cancer drug carriers are susceptible to the gap between research and practice J. Control. Release 172 2013 1045 1064
44. S. Kitano, Y. Koyama, K. Kataoka, T. Okano, and Y. Sakurai A novel drug delivery system utilizing a glucose responsive polymer complex between poly (vinyl alcohol) and poly(N-vinyl-2-pyrrolidone) with a phenylboronic acid moiety J. Control. Release 19 1992 161 170
45. N.A. Peppas Is there a future in glucose-sensitive, responsive insulin delivery systems? J. Drug Delivery Sci. Technol. 14 2004 247 256
46. B.J. Gilligan, M.C. Shults, R.K. Rhodes, and S.J. Updike Evaluation of a subcutaneous glucose sensor out to 3 months in a dog model Diabetes Care 17 1994 882 887
47. N. Wisniewski, and M. Reichert Methods for reducing biosensor membrane biofouling Colloids Surf. B: Biointerfaces 18 2000 197 219
48. P.U. Abel, and T. von Woedtke Biosensors for in vivo glucose measurement: can we cross the experimental stage Biosens. Bioelectron. 17 2002 1059 1070